Spectris 40Hz sensory stimulation preserves corpus callosum and attenuates EEG slowing in Alzheimer's: OVERTURE feasibility results
Summary
Cognito Therapeutics published detailed OVERTURE feasibility study results at AD/PD 2026. Key neurophysiology findings: (1) Spectris maintained brain volume (+0.58%) vs ADNI control decline (-0.91%) over 6 months; (2) statistically significant preservation of corpus callosum white matter tract; (3) attenuation of EEG slowing (the progressive shift from alpha to theta/delta power that tracks AD neurodegeneration); (4) EEG slowing attenuation correlated with ADCS-ADL functional preservation and MRI volume preservation; (5) Spectris enhanced cognitive event-related potentials associated with working memory processing in AD patients.
Why it matters
Five distinct neurophysiological lines of evidence from a single non-invasive at-home device trial is an unusually comprehensive result for an AD device feasibility study. Corpus callosum preservation, MRI volume maintenance, EEG biomarker normalization, functional score correlation, and working memory ERP enhancement each independently support the disease-modification hypothesis. Their convergence makes the OVERTURE data some of the most compelling Alzheimer's therapeutic evidence published from a non-pharmacological intervention.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial